source
- Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trialRegeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…
- Gate Bioscience eyes clinic trials with molecular gate drugs, backed by expanded $870M Lilly partnershipGate Bioscience is developing small-molecule drugs that block the Sec61 channel, preventing disease-causing proteins from entering cells and leading to their degradation. The company's first discl…